Anke Biotech increases Biosyngen stake, secures exclusive China rights for CAR-T therapy

Anhui Anke Biotechnology Group (Anke Biotech) will invest 30 million yuan into Biosyngen Biomedical Technology (Suzhou) Co., Ltd. (Biosyngen), increasing its stake to 21.4121% from 20.0572%. This investment recognizes Biosyngen's R&D, advanced technology platforms, and market valuation, aligning with Anke Biotech's strategy to enhance its innovative drug pipeline, particularly in CAR-T cell therapy.

Simultaneously, Anke Biotech signed a framework agreement for the exclusive agency of Biosyngen’s PA3-17 injection product in Greater China upon its market launch. PA3-17, a CD7-CAR-T cell therapy, has received new drug clinical trial approval and is recognized as a breakthrough therapy. This strategic partnership aims to integrate capital and business, securing Anke Biotech’s exclusive promotion rights for future Biosyngen products.

Both transactions, considered connected transactions, have been approved by Anke Biotech’s board of directors and independent directors, with the capital increase based on Biosyngen’s pre-investment valuation of 1.74 bn yuan. These moves are designed to foster synergistic development and strengthen Anke Biotech's market competitiveness without impacting its current operating performance.